Satellos Bioscience Inc. (MSLE) stock
Close on Nov 11, 2026Market cap $104.35MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $104.35M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -22.62%
Fundamentals
- EPS, diluted
- -$1.70
- Free cash flow
- -$23.60M
Trading
- Previous close
- $6.95
- Open
- $7.36
- Day's range
- $6.75 – $7.36
- Volume
- 21,142
- Average volume (20 days)
- 47,625
- Beta (5 years)
- 3.42
- 52-week range
- $5.30 – $13.39
- RSI (14 days)
- 45.4
- Volatility (1 year)
- 83.3%
- Relative volume
- 0.37×
- WACC
- 17.4%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MSLE | S&P 500 | Difference | MSLE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.9% | -2.4% | −7.5 pts | ||
| 3 months | -32.6% | -1.2% | −31.5 pts | ||
| Year to date | +14.8% | +12.3% | +2.5 pts | ||
| 1 year | +9.8% | +12.4% | −2.7 pts | ||
| 3 years | +155.1% | +78.8% | +76.3 pts | +36.6% | +21.4% |
| 5 years | -50.1% | +75.2% | −125.3 pts | -13.0% | +11.9% |
| 10 years | -6.3% | +311.1% | −317.4 pts | -0.6% | +15.2% |
Three years at a glance
Fiscal years 2023 to 2025, USD
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Satellos Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Satellos Bioscience
Pharmaceutical Preparations
Satellos Bioscience Inc. is a Canada-based biotechnology corporation that focuses on the research and development of pharmaceutical products and therapeutic treatments. The company's activities primarily center on developing proprietary drug candidates and advancing licensed medical products through clinical trials, regulatory submissions, and potential commercialization. Operating as a single primary segment in drug research and development, its business initiatives and therapies are aimed at treating patients and serving stakeholders within the broader healthcare and biopharmaceutical industry.
Company profile, executives and historySatellos Bioscience stock: common questions
What is Satellos Bioscience's stock price?
MSLE closed at $6.75 on Nov 11, 2026, down 2.88% on the day. Over the past 52 weeks it traded between $5.30 and $13.39.
What is Satellos Bioscience's market cap?
Satellos Bioscience was worth $104.35M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MSLE's P/E ratio?
Satellos Bioscience lost money over fiscal 2025 (diluted EPS -$1.70), so it has no meaningful P/E ratio.
Does Satellos Bioscience pay a dividend?
No. Satellos Bioscience has not paid a cash dividend over the last twelve months.
How has MSLE stock performed over the past year?
Including dividends, MSLE returned +9.8% over the past year, against +12.4% for the S&P 500.
How many MSLE shares are sold short?
0M shares were sold short at the latest FINRA report, 0.82% of the float, or 3.9 days of average trading volume.
Who are Satellos Bioscience's competitors?
Companies most similar to Satellos Bioscience by business, industry and size include PBM, COGT, APLM, QNTM, HELP.
See a number that looks wrong?